6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Rhabdomyolysis B-OSE_Labeled_AE
with O
myoglobinuria B-OSE_Labeled_AE
and O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
and O
myopathy B-OSE_Labeled_AE
( O
including O
myositis B-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Liver B-OSE_Labeled_AE
Enzyme I-OSE_Labeled_AE
Abnormalities I-OSE_Labeled_AE
[ O
see O
Warning O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Of O
4,798 O
patients O
enrolled O
in O
10 O
controlled O
clinical O
studies O
and O
4 O
subsequent O
open-label O
extension O
studies O
, O
3,291 O
patients O
were O
administered O
pitavastatin O
1 O
mg O
to O
4 O
mg O
daily O
. O

The O
mean O
continuous O
exposure O
of O
pitavastatin O
( O
1 O
mg O
to O
4 O
mg O
) O
was O
36.7 O
weeks O
( O
median O
51.1 O
weeks O
) O
. O

The O
mean O
age O
of O
the O
patients O
was O
60.9 O
years O
( O
range O
; O
18 O
years O
- O
89 O
years O
) O
and O
the O
gender O
distribution O
was O
48 O
% O
males O
and O
52 O
% O
females O
. O

Approximately O
93 O
% O
of O
the O
patients O
were O
Caucasian O
, O
7 O
% O
were O
Asian/Indian O
, O
0.2 O
% O
were O
African O
American O
and O
0.3 O
% O
were O
Hispanic O
and O
other O
. O

EXCERPT O
: O
The O
most O
frequent O
adverse O
reactions O
( O
rate O
> O
=2.0 O
% O
in O
at O
least O
one O
marketed O
dose O
) O
were O
myalgia O
, O
back O
pain O
, O
diarrhea O
, O
constipation O
and O
pain O
in O
extremity O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Kowa O
Pharmaceuticals O
America O
, O
Inc O
. O
at O
1-877-334-3464 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Studies O
Experience O
Because O
clinical O
studies O
on O
LIVALO O
are O
conducted O
in O
varying O
study O
populations O
and O
study O
designs O
, O
the O
frequency O
of O
adverse O
reactions O
observed O
in O
the O
clinical O
studies O
of O
LIVALO O
can O
not O
be O
directly O
compared O
with O
that O
in O
the O
clinical O
studies O
of O
other O
HMG-CoA O
reductase O
inhibitors O
and O
may O
not O
reflect O
the O
frequency O
of O
adverse O
reactions O
observed O
in O
clinical O
practice O
. O

Adverse O
reactions O
reported O
in O
> O
= O
2 O
% O
of O
patients O
in O
controlled O
clinical O
studies O
and O
at O
a O
rate O
greater O
than O
or O
equal O
to O
placebo O
are O
shown O
in O
Table O
1 O
. O

These O
studies O
had O
treatment O
duration O
of O
up O
to O
12 O
weeks O
. O

Table O
1 O
. O

Adverse O
Reactions* O
Reported O
by O
> O
=2.0 O
% O
of O
Patients O
Treated O
with O
LIVALO O
and O
> O
Placebo O
in O
Short-Term O
Controlled O
Studies O
* O
Adverse O
reactions O
by O
MedDRA O
preferred O
term O
. O

AdverseReactions* O
PlaceboN= O
208 O
LIVALO1 O
mgN=309 O
LIVALO2 O
mgN=951 O
LIVALO4 O
mgN=1540 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2.9 O
% O
3.9 O
% O
1.8 O
% O
1.4 O
% O
Constipation B-OSE_Labeled_AE
1.9 O
% O
3.6 O
% O
1.5 O
% O
2.2 O
% O
Diarrhea B-OSE_Labeled_AE
1.9 O
% O
2.6 O
% O
1.5 O
% O
1.9 O
% O
Myalgia B-OSE_Labeled_AE
1.4 O
% O
1.9 O
% O
2.8 O
% O
3.1 O
% O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
1.9 O
% O
2.3 O
% O
0.6 O
% O
0.9 O
% O
Other O
adverse O
reactions O
reported O
from O
clinical O
studies O
were O
arthralgia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
and O
nasopharyngitis B-OSE_Labeled_AE
. O

The O
following O
laboratory O
abnormalities O
have O
also O
been O
reported O
: O
elevated B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
, O
transaminases O
, O
alkaline O
phosphatase O
, O
bilirubin O
, O
and O
glucose O
. O

In O
controlled O
clinical O
studies O
and O
their O
open-label O
extensions O
, O
3.9 O
% O
( O
1 O
mg O
) O
, O
3.3 O
% O
( O
2 O
mg O
) O
, O
and O
3.7 O
% O
( O
4 O
mg O
) O
of O
pitavastatin-treated O
patients O
were O
discontinued O
due O
to O
adverse O
reactions O
. O

The O
most O
common O
adverse O
reactions O
that O
led O
to O
treatment O
discontinuation O
were O
: O
elevated B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
( O
0.6 O
% O
on O
4 O
mg O
) O
and O
myalgia B-OSE_Labeled_AE
( O
0.5 O
% O
on O
4 O
mg O
) O
. O

Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
rash B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
and O
urticaria B-OSE_Labeled_AE
have O
been O
reported O
with O
LIVALO O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
LIVALO O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Adverse O
reactions O
associated O
with O
LIVALO O
therapy O
reported O
since O
market O
introduction O
, O
regardless O
of O
causality O
assessment O
, O
include O
the O
following O
: O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
fatal B-NonOSE_AE
and O
non-fatal O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
and O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
. O

There O
have O
been O
rare O
postmarketing O
reports O
of O
cognitive B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
( O
e.g. O
, O
memory B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
forgetfulness B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
) O
associated O
with O
statin O
use O
. O

These O
cognitive B-OSE_Labeled_AE
issues I-OSE_Labeled_AE
have O
been O
reported O
for O
all O
statins O
. O

The O
reports O
are O
generally O
nonserious O
, O
and O
reversible O
upon O
statin O
discontinuation O
, O
with O
variable O
times O
to O
symptom O
onset O
( O
1 O
day O
to O
years O
) O
and O
symptom O
resolution O
( O
median O
of O
3 O
weeks O
) O
. O

There O
have O
been O
rare O
reports O
of O
immune B-OSE_Labeled_AE
- I-OSE_Labeled_AE
mediated I-OSE_Labeled_AE
necrotizing I-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
associated O
with O
statin O
use O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

